Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash & Current Investments (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Cash & Current Investments for 16 consecutive years, with $81.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 2.46% to $81.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $81.2 million through Dec 2025, up 2.46% year-over-year, with the annual reading at $81.2 million for FY2025, 2.46% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $81.2 million at Anika Therapeutics, up from $80.2 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $124.2 million in Q4 2021, with the low at $75.4 million in Q1 2025.
  • Average Cash & Current Investments over 5 years is $99.3 million, with a median of $96.9 million recorded in 2021.
  • The sharpest move saw Cash & Current Investments crashed 32.69% in 2021, then soared 34.04% in 2022.
  • Over 5 years, Cash & Current Investments stood at $124.2 million in 2021, then fell by 2.64% to $121.0 million in 2022, then fell by 21.38% to $95.1 million in 2023, then fell by 16.7% to $79.2 million in 2024, then rose by 2.46% to $81.2 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $81.2 million, $80.2 million, and $77.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.